The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol
An Open-label, Crossover Study of the Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol
Sponsor: Athenex, Inc.
Terminated
STUDY HALTED DUE TO FINANCIAL CONTRAINTS
Other terminated trials from Athenex, Inc.
More terminations from Athenex, Inc.
A PHASE1 clinical study on Solid Tumor, Adult, this trial is terminated or withdrawn. The trial is conducted by Athenex, Inc. and has accumulated 10 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Dec 2022 — Jun 2023 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Mar 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Oct 2021 — Mar 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Apr 2019 — Mar 2020 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Athenex, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .